BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1129 related articles for article (PubMed ID: 17245363)

  • 1. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
    Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
    Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
    Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Thomas A; Stevenson LA; Wease KN; Price MR; Baillie G; Ross RA; Pertwee RG
    Br J Pharmacol; 2005 Dec; 146(7):917-26. PubMed ID: 16205722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
    Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG
    Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
    Bolognini D; Cascio MG; Parolaro D; Pertwee RG
    Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzophenanthridine alkaloid, piperonyl butoxide and (S)-methoprene action at the cannabinoid-1 receptor (CB1-receptor) pathway of mouse brain: Interference with [(3)H]CP55940 and [(3)H]SR141716A binding and modification of WIN55212-2-dependent inhibition of synaptosomal l-glutamate release.
    Dhopeshwarkar AS; Nicholson RA
    Eur J Pharmacol; 2014 Jan; 723():431-41. PubMed ID: 24211785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.
    McIntosh BT; Hudson B; Yegorova S; Jollimore CA; Kelly ME
    Br J Pharmacol; 2007 Dec; 152(7):1111-20. PubMed ID: 17922024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
    Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
    Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
    Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
    Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.
    Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG
    Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L; Howlett AC; Mukhopadhyay S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
    Rahn EJ; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tamoxifen derivative ridaifen-B is a high affinity selective CB
    Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
    Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
    Johns DG; Behm DJ; Walker DJ; Ao Z; Shapland EM; Daniels DA; Riddick M; Dowell S; Staton PC; Green P; Shabon U; Bao W; Aiyar N; Yue TL; Brown AJ; Morrison AD; Douglas SA
    Br J Pharmacol; 2007 Nov; 152(5):825-31. PubMed ID: 17704827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
    Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
    J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
    Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.